Research & Development
Boehringer Ingelheim Regional Center Vienna is dedicated to drug discovery for innovative cancer medicines. A team of more than 250 scientists combine expertise in cancer immunology and cancer biology, as well as genomics, pharmacology, medicinal chemistry, structural biology, screening and pharmacokinetics to identify novel medicines for the treatment of cancer. In the Cancer Immunology Department we are looking for a highly motivated and result-oriented scientist (m/f) with a strong background and expertise in human cancer immunology and experience in setting up and steering academic:pharma collaborations as well as partnerships with CROs in the field of tumour explant analysis and patient-derived organoids.
The Scientific Director-External Research in Human Cancer Immunology will act as a key interface with the external academic community and CROs. He/she will have a particular focus on establishing human tumour ex vivo models that are used to characterize and understand pathways that modulate immune cells in the context of the tumour microenvironment.
We offer a market-competitive salary package in line with your qualification, experience and individual competencies. Additionally we offer a modern company pension scheme, learning and development options as well as a wide range of social benefits. The base pay is composed of a market oriented excess payment and the respective amount according to the Austrian collective agreement (at least EUR 70,000 gross per year/full-time).
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.
Your application will be reviewed by our recruiting team as well as the respective department. Therefore, we do not state a specific contact person and kindly ask you to use a general salutation in your application.